ArticleWorld journal of diabetes2022
Acarbose is again on the stage.
Article in World journal of diabetes, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 38 citations in OpenAlex.
- Phytochemical Analysis, GC-MS Chemical Profiling, and In Vitro Antidiabetic Evaluation of South AfricanCurrent issues in molecular biology · 2026Article
- α-Glucosidase-driven metabolism as a potential therapeutic vulnerability inFrontiers in microbiology · 2026Review
- Activity guided discovery of dual inhibitors of α-glucosidase and β-glucuronidase from the leaves ofJournal of enzyme inhibition and medicinal chemistry · 2025Article
- Acarbose ameliorates Western diet-induced metabolic and cognitive impairments in the 3xTg mouse model of Alzheimer's disease.GeroScience · 2025Article
- Extraction of mannooligosaccharides from spent coffee grounds and its application for functional jelly with improved physical properties and immunomodulatory effect.Journal of food science and technology · 2025Article
- The Impact of Cooking on Antioxidant and Enzyme Activities in Ruichang Yam Polyphenols.Foods (Basel, Switzerland) · 2024Article
- Total Content and Composition of Phenolic Compounds fromMolecules (Basel, Switzerland) · 2024Article
- Article
- Antidiabetic Potential of Novel 1,3,5-Trisubstituted-2-Thioxoimidazloidin-4-One Analogues: Insights into α-Glucosidase, α-Amylase, and Antioxidant Activities.Pharmaceuticals (Basel, Switzerland) · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acarbose is an agent that has been used to treat type 2 diabetes for about 30 years; it prevents postprandial hyperglycemia by inhibiting carbohydrate digestion in the small intestine. Since incretin-based treatments have been preferred over the last 10 to 15 years, the use of acarbose is not as common in treating type 2 diabetes as before. Some studies have shown that acarbose also produces a weight-loss effect by increasing glucagon-like peptide 1 (GLP-1). The positive effect of acarbose on GLP-1, and increasing evidence that it provides cardiovascular protection, suggests that acarbose may again be considered among the first-choice antidiabetic agents, as it was in the 1990s.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.